- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/32 - Oxygen atoms
Patent holdings for IPC class C07D 209/32
Total number of patents in this class: 127
10-year publication summary
|
5
|
0
|
7
|
5
|
6
|
4
|
9
|
15
|
9
|
6
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1800 |
5 |
| Janssen Pharmaceuticals, Inc. | 433 |
4 |
| Katholieke Universiteit Leuven | 1191 |
4 |
| NovaTarg, Inc. | 4 |
3 |
| Terran Biosciences, Inc. | 94 |
3 |
| Bristol-myers Squibb Company | 4898 |
2 |
| Abbott Laboratories | 2399 |
2 |
| Centre National de La Recherche Scientifique | 10418 |
2 |
| Amira Pharmaceuticals, Inc. | 70 |
2 |
| Ilypsa, Inc. | 10 |
2 |
| Eisai R&D Management Co., Ltd. | 1233 |
2 |
| Avalyn Pharma Inc. | 33 |
2 |
| Actimed Therapeutics Limited | 25 |
2 |
| Advitech Advisory and Technologies SA | 4 |
2 |
| Enveric Biosciences Canada Inc. | 62 |
2 |
| Novartis AG | 10849 |
1 |
| F. Hoffmann-La Roche AG | 7925 |
1 |
| Sandoz AG | 1422 |
1 |
| Boehringer Ingelheim International GmbH | 4650 |
1 |
| Ajinomoto Co., Inc. | 2295 |
1 |
| Other owners | 83 |